electroCore Inc. (ECOR)
| Bid | 6 |
| Market Cap | 46.76M |
| Revenue (ttm) | 24.21M |
| Net Income (ttm) | -11.43M |
| EPS (ttm) | -1.59 |
| PE Ratio (ttm) | -4.09 |
| Forward PE | -29.38 |
| Analyst | Buy |
| Ask | 7.47 |
| Volume | 164,432 |
| Avg. Volume (20D) | 148,563 |
| Open | 6.82 |
| Previous Close | 6.81 |
| Day's Range | 6.33 - 6.93 |
| 52-Week Range | 5.32 - 19.49 |
| Beta | 0.25 |
About ECOR
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or i...
Analyst Forecast
According to 2 analyst ratings, the average rating for ECOR stock is "Buy." The 12-month stock price forecast is $25.5, which is an increase of 292.31% from the latest price.
Stock Forecasts
1 day ago · proactiveinvestors.co.uk
Ecora eyes strong 2025 as copper and cobalt streams ramp upEcora Resources PLC (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF) is expecting a sharp increase in royalty income in 2025, driven by rising production volumes across its copper and cobalt assets and supported by ...
1 month ago · proactiveinvestors.co.uk
Ecora Resources getting no credit for significant growth potential, says brokerEcora Resources PLC (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF) reported portfolio income of US$63 million for 2024 was slightly higher than market estimates, says broker Peel Hunt. Management highlighted that ...
1 month ago · proactiveinvestors.co.uk
Ecora Resources boosted by record copper and cobalt productionRoyalty specialist Ecora Resources PLC (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF) said its income in its fourth quarter was boosted by record production volumes at the Voisey's Bay (cobalt) and Mantos Blancos ...
2 months ago · seekingalpha.com
electroCore: An Opportunity In Medical And Wellness Device InnovationelectroCore, Inc. (ECOR) shows promising growth with a 45% YoY revenue increase and a 38% loss reduction, despite missing revenue expectations. The company's gammaCore device is FDA-cleared for headac...
2 months ago · seekingalpha.com
electroCore Has Only Just Begun To Scratch The Surface Of Its Huge TAMelectroCore's gammaCore, an FDA-approved nVNS device, generates recurring revenue and has significant expansion potential within the VA system and other healthcare channels. The company is diversifyin...